Inclusion Criteria:

   - Histologically confirmed Hodgkin's lymphoma or Non-Hodgkin's lymphoma receiving Q14,
   Q21, or Q28 day CHOP, ICE, ESHAP, or DHAP chemotherapy; with or without Rituximab

   - Has adequate bone marrow function; platelet count > 100 x 10^9/L on the day of
   initiation of the on study chemotherapy of the next treatment cycle and absolute
   neutrophil count, ANC > or = 1 x 10^9/L, and hemoglobin > or = 9.5 g/dL

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

   - Has adequate liver function

   - must be able to receive the same chemotherapy regimen during the first treatment cycle
   as was received during the prior qualifying cycle

   - must experience Common Terminology Criteria (CTC) grade 3 or 4 thrombocytopenia
   (platelet count < 50 x 10^9/L) as a result of the chemotherapy administered in the
   cycle immediately preceding study entry

   - has serum creatinine concentration < or = 2 mg/dl

Exclusion Criteria:

   - More that 1 prior relapse chemotherapy regimen

   - Sepsis, disseminated coagulation or any other condition that may exacerbate
   thrombocytopenia

   - Significant bleeding (CTC grade 3 or 4)

   - History of thromboembolic disease

   - Subjects who are identified by clinical history and/or serological testing to have
   either acute or chronic hepatitis B or C infection or to be HIV positive

   - Use of any nitrosourea or mitomycin-C

   - Has received any thrombocytopenic growth factor

   - Has received a marrow or peripheral blood stem cell infusion

   - Known hypersensitivity to any recombinant E. coli-derived product